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Objectives The purpose of this study was to investigate neuropeptides in patients presenting with symptoms of acute cere-
brovascular disease.
Background The precursor neuropeptides proenkephalin A (PENK-A) and protachykinin (PTA) are markers of blood-brain bar-
rier integrity and have been recently discussed in vascular dementia and neuroinflammatory disorders.
Methods In a prospective observational study, we measured plasma PENK-A and PTA concentrations in 189 consecutive pa-
tients who were admitted with symptoms of acute stroke. Plasma concentrations were determined by sandwich im-
munoassay; lower detection limits were 15.6 pmol/l (PENK-A) and 22 pmol/l (PTA). Clinical outcome was assessed at
3 months for mortality, major adverse cerebro/cardiovascular events, and functional outcome (modified Rankin scale).
Results PENK-A was significantly elevated in patients with ischemic stroke (n  124; 65.6%) compared to patients with
transient ischemic attack (n  16; 8.5%) and to patients with nonischemic events (n  49; 25.9%): median
(interquartile range), stroke 123.8 pmol/l (93 to 160.5); transient ischemic attack 114.5 pmol/l (85.3 to 138.8);
and nonischemic event 102.8 pmol/l (76.4 to 137.6; both groups vs. stroke p  0.05). High concentrations of
PENK-A, but not PTA, were related to severity of stroke as assessed by National Institutes of Health Stroke Scale
(NIHSS [r  0.225; p  0.002]) and to advanced functional disability (modified Rankin Scale score 3 to 6 vs.
0 to 2: 135.1 pmol/l [99.2 to 174.1] vs. 108.9 pmol/l [88.6 to 139.5]; p  0.014). After adjusting for age,
NIHSS, and brain lesion size (computed tomography), PENK-A predicted mortality (hazard ratio [HR] for log-10
PENK-A in pmol/l: 4.52; 95% confidence interval [CI]: 1.1 to 19.0; p  0.05) and major adverse cerebro/cardio-
vascular events (HR: 6.65; 95% CI: 1.8 to 24.9; p 0.05). Patients in the highest quartile of PENK-A (cutoff153
pmol/l) had an increased risk of mortality (HR: 2.40; 95% CI: 1.02 to 5.40; p  0.05) and of major adverse cere-
bro/cardiovascular events (HR: 2.23; 95% CI: 1.10 to 4.54; p  0.05).
Conclusions PENK-A is a prognostic biomarker in the acute phase of ischemic stroke. Elevated PENK-A concentrations are
associated with ischemic stroke, severity of cerebral injury, and may have prognostic value for fatal and nonfatal
events. (J Am Coll Cardiol 2012;60:346–54) © 2012 by the American College of Cardiology Foundation
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society, being in third position behind heart disease and
cancer in the United States (1) and even in first position
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July 24, 2012:346–54 PENK-A Predicts Outcome in Stroke Patientsremains biased by subjective judgment (3). Moreover, the
prognosis may vary, although stroke and TIA share patho-
physiological mechanisms and their therapeutic conse-
quences have assimilated (4).
Cerebral infarctions may be further itemized to markers
associated with infarct size (e.g., astroglial protein S-100B) and
with damage to the blood-brain barrier (BBB, for example,
c-Fn, matrix metalloproteinase-9 (MMP-9) (5). Recent studies
dentified stable precursor fragments of the neuropeptides
nkephalin (proenkephalin A [PENK-A]) and substance P
protachykinin A [PTA]) as potent markers of BBB integrity
6,7). Both mature neuropeptides are active as neurotransmit-
ers and are involved in nociception and immune stimulation.
hey have been implicated in the pathophysiology of certain
europathologies, including Parkinson’s disease, Alzheimer’s
isease, and severe head injury (8). Elevated plasma levels of
ethionine-enkephalin in patients after acute cerebral in-
arction have been reported (9). The role of enkephalins in
troke is, however, incompletely understood as both pres-
nce and absence of a neuroprotective effect of opioid
eceptor stimulation have been described (10,11).
Early identification of patients with increased risk is of
reat importance in the process of clinical evaluation of
mergency patients. In the era of flowchart-guided deci-
ion trees, the identification of novel biomarkers is of
rowing importance for both diagnostic and prognostic
valuation. Similar to the successful use of biomarkers in
he management of acute cardiac events, there are in-
reasing efforts to establish biomarker-based tests for the
valuation of patients admitted to the stroke unit for
linical decision making and risk assessment (12,13). In
ontrast to acute cardiac events, however, validated mark-
rs for ischemic stroke are lacking (14), and current
uidelines make no recommendations for the use of
iomarkers for risk stratification in stroke.
The aim of the present study was to evaluate PENK-A
nd PTA in patients presenting with symptoms of acute
erebrovascular disease in relation to stroke severity and to
utcome. We hypothesized that PENK-A and PTA may be
ssociated with a poorer outcome.
ethods
tudy population and enrollment criteria. Our study
opulation comprised 189 consecutive patients, who pre-
ented with symptoms of acute stroke to the emergency
epartment of the University Hospital Tuebingen between
anuary 2008 and May 2009. The median time between
ymptom onset and hospital admission was 4.5 h (interquar-
ile range [IQR] 1.3 to 19.8 h). Patients with symptom
nset 24 h before initial assessment on hospital admission
ere not considered as acute stroke patients and were
herefore excluded. Blood was drawn from the anticubital
ein within 1 h of hospital admission. All patients under-
ent cranial computed tomography (CT [Siemens Soma-om Sensation16, Erlangen, Germany]) within 90 min afterospital admission. The scans
ere performed on a Siemens
canner using 4.5-mm slices. Im-
ges were analyzed by an experi-
nced neuroradiologist, as de-
cribed previously (15). Brain
esion volume was calculated ac-
ording to the formula for irreg-
lar volumes (16).
Exclusion criteria were age
18 years and inability to pro-
ide informed consent. The acute
erebral events were grouped ac-
ording to the type of event as
IA, stroke, or nonischemic
vent. Transient ischemic attack
as defined by the duration of
ymptoms of stroke 24 h and
bsence of brain lesion on CT
4). Stroke was considered with
ymptoms lasting 24 h after
nset and with the evidence of an
cute clinically relevant brain le-
ion in patients with rapidly van-
shing symptoms in CT. Previ-
usly defined etiologic subgroups
f stroke were determined ac-
ording to the TOAST (Trial of
RG10172 in Acute Stroke
reatment) criteria as: 1) large-
rtery atherosclerosis (LAA);
) cardioembolism; 3) small-
essel occlusion; 4) stroke of other determined etiology; or
) stroke of undetermined etiology (17). Stroke severity was
ssessed according to the National Institutes of Health
troke Scale (NIHSS) on hospital admission (18). Nonisch-
mic events were considered if none of the previous criteria
pplied but 1 of the following disorders was identified:
pileptic seizure (n  15), medication interaction (n  2),
ransient visual disorder (n  4), paroxysmal positioning
ertigo (n  5), migraine with aura (n  11), psychogen
(n  2), brain tumor (n  4), and alcohol abuse (n  6).
Patients with higher NIHSS score (12) or intracerebral
hemorrhage had been excluded. The study was approved by
the local ethics committee.
Clinical follow-up and functional outcome. Clinical out-
come was assessed after 3-month follow-up and was per-
formed by hospital chart analysis and by a pre-defined
structured telephone interview. For functional outcome
assessment, the modified Rankin Scale (mRS) scoring was
applied according to previous description (19): 0  no
ymptoms at all; 1  no significant disability despite
ymptoms; 2  slight disability; 3  moderate disability;
 moderately severe disability; 5  severe disability; 6 
Abbreviations
and Acronyms
AUC  area under the
curve
BBB  blood-brain barrier
CI  confidence interval
CT  computed
tomography
HR  hazards ratio
LAA  large-artery
atherosclerosis
MACCE  major adverse
cerebro/cardiovascular
event(s)
mRS  modified Rankin
Scale
NIHSS  National
Institutes of Health Stroke
Scale
NRI  net reclassification
improvement
OR  odds ratio
PENK-A  Proenkephalin A
PTA  Protachykinin A
ROC  receiver-operating
characteristic
TIA  transient ischemic
attack
TOAST  Trial of
ORG10172 in Acute Stroke
Treatmentdead.
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PENK-A Predicts Outcome in Stroke Patients July 24, 2012:346–54Blood sampling. The ethylenediaminetetraacetic acid
samples were immediately centrifuged, aliquoted, and
stored at 80°C until batch analysis. Routine biochemical
parameters were assessed in the standard clinical laboratory.
Measurement of PENK-A and PTA plasma level con-
centrations. Plasma samples were blinded as to the under-
lying diagnosis of the patients for further assessments.
Midregional proenkephalin A 119–159 (PENK-A) and
N-terminal protachykinin A (PTA) were assessed by a
newly developed chemoluminescence sandwich immunoas-
say, using a chemiluminescence platform and coated tube
technique, as described previously (Immunochemical Intel-
ligence GmbH, Berlin, Germany) (6,7). All assessments
were run in duplicates. For the measurement of PENK-A,
monoclonal antibodies against the amino acids sequence
121-134 of PENK-A were used. Polyclonal antibodies
against the amino acids sequence 139–155 were labeled
with methyl-acridinium N-hydroxysuccinimide and used as
tracer. The PTA was measured using monoclonal mouse
antibodies against the amino acid sequence 3–22 of PTA,
and monoclonal antibodies against amino acids 21–36 were
labeled for tracing.
Intra-assay and interassay coefficients of variation were
10% and 15%, respectively, for PTA, and 12% and
13% for PENK-A. Lower detection limits were at 13.5
pmol/l and 15.6 pmol/l for PTA and PENK-A, respec-
tively. The normal range of PENK-A is from 41.8 to 131
pmol/l (median 62.3 pmol/l), and for PTA, from 30.8 to
179.2 pmol/l (median 98.7 pmol/l). Normal ranges are not
dependent on age or sex.
Baseline Patient Characteristics and Medical TrTable 1 Baseline Patient Characteristics an
Characteristics
All
(n  189)
Age, yrs 71 14
Sex
Female 81 (42.9)
Male 108 (57.1)
CVD risk factors
Arterial hypertension 131 (69.3)
Hyperlipidemia 86 (45.5)
Diabetes mellitus 52 (27.5)
Family history of CVD 15 (7.9)
Smoking 36 (19)
History of CAD 60 (31.7)
Atrial fibrillation 64 (33.9)
Medication
ACE inhibitors 73 (38.6)
Angiotensin-receptor blockers 14 (7.4)
Beta-blockers 83 (43.9)
Statins 36 (19)
Aspirin 28 (14.8)
Clopidogrel 4 (2.1)
Vitamin K antagonist 14 (7.4)Values are mean  SD or n (%).
ACE  angiotensin-converting enzyme; CAD  coronary artery disease; CVDStatistics. A 2-tailed probability value of  0.05 was
considered as statistically significant. Variables are presented
as median and IQR. Group comparison was performed by
analysis of variance, by Fisher’s post-hoc test, and by
Kruskall-Wallis test as appropriate. PENK-A and PTA
were log-transformed for statistical analyses as the
Kolmogorov-Smirnov test revealed nonnormal distribution
of the variables. Associations between novel biomarkers and
clinical parameters were made by Pearson correlation. Lo-
gistic regression was applied as appropriate.
Adjustment for possible confounders was performed by
the multifactorial analysis of covariance for the decadic
logarithms of PENK-A and PTA, which included age,
sex, risk factors, and clinical parameter such as arterial
hypertension, diabetes mellitus, hyperlipidemia, family
history of coronary artery disease (CAD), smoking,
concomitant CAD, atrial fibrillation, brain lesion size,
laboratory parameters, and medication at the time of
admission.
Outcome was assessed for the coprimary endpoint of
all-cause mortality and the composite endpoint of all-
cause mortality, stroke reoccurrence, and nonfatal myo-
cardial infarction (MACCE) (20). Cox proportional
hazard analysis and log-rank test (Mantel-Cox) were
used for outcome analyses, and hazard ratios (HR) and
95% confidence intervals (CI) are presented. Odds ratio
(OR) for functional outcome is reported. Unadjusted
models and adjusted for age, NIHSS, and brain lesion
size (PENK-A only) were calculated. For outcome anal-
ysis, we assessed biomarkers as continuous variables and
ent on Hospital Admissiondical Treatment on Hospital Admission
TIA
(n  16)
Stroke
(n  124)
Nonischemic
(n  49)
7.9 16.5 73.1 11.2 67 17
6 (37.5) 55 (44.4) 20 (40.8)
10 (62.5) 69 (55.6) 29 (59.2)
12 (75) 95 (76.6) 24 (40.8)
11 (68.8) 63 (50.8) 12 (24.5)
5 (31.3) 38 (30.6) 9 (18.4)
1 (6.3) 10 (8.1) 4 (8.2)
2 (12.5) 27 (21.8) 7 (14.3)
2 (12.5) 46 (37.1) 12 (24.5)
4 (25) 43 (34.7) 17 (34.7)
2 (12.5) 55 (44.4) 16 (32.7)
1 (6.3) 10 (8.1) 3 (6.1)
6 (37.5) 65 (52.4) 12 (24.5)
4 (25) 17 (13.7) 15 (30.6)
1 (6.3) 16 (12.9) 11 (22.4)
1 (6.3) 2 (1.6) 1 (2)
1 (6.3) 3 (2.4) 10 (20.4)eatmd Me
6 cerebro/cardiovascular disease; TIA  transient ischemic attack.
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Kaplan-Meier survival plots are shown for illustrative
purpose.
Time-dependent receiver-operating characteristic (ROC)
curves and time-dependent area under the curve (AUC)
values are determined from censored survival data using the
Kaplan-Meier method (21). To assess differences between
the AUCs in ROC analysis, a DeLong test was applied
(Analyse-It software, version 2.20, Microsoft, Redmond,
Washington).
To evaluate the “added predictive ability” of both
PENK-A and PTA, a net reclassification improvement
(NRI) was applied (22). Adapted from the Essen stroke risk
score (23), our base clinical model for NRI computation
comprised age 65 to 74 years (1 point), age 75 years (2
points), arterial hypertension (1 point), hyperlipidemia
(1 point), diabetes mellitus (1 point), family history of CAD
(1 point), smoking (1 point), concomitant CAD (1 point),
and atrial fibrillation (1 point), which was categorized into
scores of lower (0 to 2 points), intermediate (3 to 6 points),
and higher risk (6 points). The NRI for PENK-A and
PTA was determined based on 3 risk categories using Stata
statistical software, Stata/IC 10.1 (StataCorp, College Sta-
tion, Texas).
All other statistical analyses were performed using R
version 2.5.1 (Library Design, Hmisc, ROCR), PASW
Statistics version 18.0 (IBM SPSS, Chicago, Illinois), and
Statview 4.5 (SAS Institute, Cary, North Carolina).
Results
Study population. We evaluated a total of 189 patients
who were consecutively admitted to the emergency depart-
ment for suspected stroke. In all patients, the diagnosis was
determined by the duration of symptoms and by CT scan.
Among these patients, 124 (65.6%) presented with stroke,
16 (8.5%) with TIA, and 49 (25.9%) with nonischemic
events. During 3-month follow-up, 5 patients were lost, and
outcome assessment after 3 months was completed in 184
patients (97.4%). The demographic details are given in
Table 1.
Biomarker assessment. The PENK-A concentration was
significantly elevated in patients with stroke (median
[IQR]): 123.8 pmol/l [93 to 160.5]) compared to patients
with TIA (114.5 pmol/l [85.3 to 138.8]) and to patients
with nonischemic events (102.8 pmol/l [76.4 to 137.6];
both groups vs. stroke p  0.05) (Fig. 1A). PTA did not
show significant differences between these groups (stroke
56.1 pmol/l [39.8 to 73.6]; TIA 46.2 pmol/l [35 to 58.9];
and nonischemic 53.8 pmol/l [39.8 to 66.4]; all nonsignif-
icant) (Fig. 1C).
The PENK-A concentration increased in parallel to
increasing severity of stroke as defined by NIHSS classes
(r  0.225; p  0.002) (Fig. 2A). The median CT lesion
size was 1.5 ml (IQR: 0.1 to 77.5). Similar to the association
with NIHSS, concentration of PENK-A correlated withbrain lesion size in stroke patients (r  0.325; p  0.001)
(Fig. 2B). The associations with NIHSS and lesion size
were not seen for PTA (data not shown). However, con-
centration of PENK-A positively correlated with PTA (r 
0.641; p  0.001) (Fig. 2C).
Analysis of patient subgroups according to etiology
showed a 40% increase of PENK-A concentrations in
patients with large-artery atherosclerosis (TOAST1; p 
0.019) (Fig. 1B) as compared to patients without stroke.
Adjustment for possible confounders was performed by
the multifactorial analysis of covariance for the decadic
logarithms of PENK-A (Table 2) and PTA (Online
Table 1). Apart from CT lesion size with PENK-A (p 
0.019) and in a trend with PTA (p  0.077), associations
of both biomarkers were found to be independent of age,
sex, cerebro/cardiovascular risk factors, baseline conven-
tional laboratory parameters such as creatinine, creatine
kinase, blood glucose, C-reactive protein, platelet count,
Figure 1 Neuropeptides PENK-A and
PTA in Association With Stroke
(A) Elevated plasma levels of proenkephalin A (PENK-A) in patients with
stroke compared to patients with transient ischemic attacks (TIA) and to
patients with nonischemic cerebral events. (B) Subgroup analysis of
PENK-A levels in patients according to stroke etiology (TOAST1, large-artery
atherosclerosis;TOAST2, cardioembolism) compared to patients with non-
ischemic events. (C) Plasma levels of protachykinin (PTA) in patients with
stroke compared to patients with transient ischemic attack and to patients
with nonischemic cerebral events. (D) Subgroup analysis of PTA plasma lev-
els in patients according to stroke etiology compared to patients with non-
ischemic events. TOAST  Trial of ORG10172 in Acute Stroke Treatment.and medical treatment at the time of admission.
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total of 24 patients died (12.6%), and 34 (17.9%) patients
experienced the composite MACCE endpoint (recurrent
stroke n 6; 3.2%; myocardial infarction n 4; 2.1%). The
PENK-A levels on admission in the 24 patients who
subsequently died were significantly elevated compared to
those of survivors (146.6 pmol/l [101.4 to 191.7] vs. 112.1
pmol/l [84.9 to 139.3]; p  0.004). In patients who
experienced the composite endpoint, PENK-A was also
elevated compared to patients without adverse outcome
(140.7 pmol/l [89.7 to 191.7] vs. 112.0 pmol/l [86.2 to
137.8]; p 0.002). No significant differences were observed
for PTA for both outcome measures.
Outcome analysis. In Cox proportional hazard analysis,
PENK-A predicted all-cause mortality (all log-10
PENK-A in pmol/l: HR: 8.65; 95% CI: 2.7 to 27.6; p 
0.001) and composite outcome of death, recurrent stroke,
and myocardial infarction (HR: 8.19; 95% CI: 2.9 to 23.1;
p  0.0001). After adjustment for age, NIHSS, and brain
lesion size, PENK-A remained significantly predictive of
total mortality (HR: 4.52; 95% CI: 1.1 to 19.0; p  0.03)
and of the composite endpoint (HR: 6.65; 95% CI: 1.8 to
24.9; p  0.005). For PTA, no significant association with
outcome was observed. Patients in the highest quartile of
PENK-A (PENK-A 153 pmol/l) had a threefold higher
risk at 3 months for mortality (HR: 3.29; 95% CI: 1.47 to
Figure 2 Correlation of PENK-A and PTA
(A) Correlation of proenkephalin A (PENK-A) plasma concentration with clinical sev
(B) Correlation of plasma concentrations of PENK-A and protachykinin (PTA). (C) S
centration with brain lesion size on computed tomography.7.35; p  0.0037), and more than twofold higher risk forthe composite endpoint as compared to the lower 3 quartiles
(HR: 2.73; 95% CI: 1.38 to 5.41; p 0.0040) (Fig. 3A and 3B).
Multivariate adjustment did not change the significant
findings (mortality HR: 2.40; 95% CI: 1.02 to 5.40;
composite outcome HR: 2.23; 95% CI: 1.10 to 4.54; both
p  0.05). The ROC analysis of PENK-A revealed an
AUC of 0.64 (95% CI: 0.50 to 0.77) for all-cause mortality,
and 0.62 (95% CI: 0.50 to 0.74) for the composite MACCE
endpoint. For PTA, we found AUCs of 0.59 (95% CI: 0.46
to 0.71) for death and 0.59 (95% CI: 0.47 to 0.70) for
composite endpoint. Comparison of PENK-A and PTA
AUCs did not reach a significant level for all-cause death (p 
0.34) and for the combined endpoint (p  0.55). Compar-
ing ROC curves of both biomarkers to age and NIHSS was
nonsignificant as well for all-cause death (PENK-A vs. age,
p 0.48; PTA vs. age, p 0.84; PENK-A vs. NIHSS, p
.12; PTA vs. NIHSS, p  0.37) and for the composite
ndpoint (PENK vs. age, p  0.46; PTA vs. age, p  0.69;
ENK vs. NIHSS, p  0.23; PTA vs. NIHSS, p  0.37).
The added value for higher PENK-A and PTA values as
compared to the clinical model with 3 risk categories
provided for all-cause death an NRI  20.2% (PENK-A,
 0.026) and an NRI  6.0% (PTA, p  0.439), and for
composite endpoint an NRI  29.2% (PENK-A, p 
.006) and an NRI  22.5% (PTA, p  0.002) (Online
f stroke according to National Institutes of Health Stroke Scale (NIHSS) score.
to the association with clinical severity, we found a correlation of PENK-A con-erity o
imilarTables 2 and 3).
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July 24, 2012:346–54 PENK-A Predicts Outcome in Stroke PatientsFunctional outcome. Functional capacity was assessed af-
ter 3 months, patients have been assessed by mRS. A high
mRS score (score 3) was found in patients with an
enhanced PENK-A concentration compared to patients
with a lower concentration (mRS score 3 to 6 vs. 0 to 2,
135.1 pmol/l [IQR: 99.2 to 174.1] vs. 108.9 pmol/l [IQR:
88.6 to 139.5]; p  0.014) (Fig. 3C). Thus, patients with
the highest quartile of PENK-A also had a significantly
increased risk for the development of moderate to higher
full functional disability (mRS score 3) at 3 months
(unadjusted OR: 2.5; 95% CI: 1.3 to 5.1; p  0.009). After
adjustment for age and brain lesion size, the highest quartile
remained a significant predictor of impaired functional
outcome (OR: 2.67; 95% CI: 1.14 to 6.25; p 0.02). When
NIHSS was added to the multivariate model, however, only
a trend for association remained (OR: 2.4; 95% CI: 0.9 to
6.44; p  0.08).
Subgroup analysis. Analysis of stroke patients according to
TOAST subgroups (TOAST1, n  47; TOAST2, n  43;
TOAST3, n  3; TOAST4, n  5; TOAST5, n  26)
showed that patients with large-artery atherosclerosis
(TOAST1) had a significantly increased PENK-A (122.9
pmol/l [95 to 201.8]) expression compared to patients
Multifactorial Analysis of Covariance for the DecadicLogarithm of the Pla ma ncentrati n of PENK-ATable 2 Multifactorial A lysis o Covarian e for the DecadicLogarithm of the Plasma Concentration of PENK-A
Category Factor
Effect
Size (F)
p
Value
Age Years 1.452 0.231
Sex Male vs. female 0.963 0.329
Risk factors and Arterial hypertension 0.035 0.853
Hyperlipidemia 0.002 0.965
Diabetes mellitus 3.857 0.053
Family history of CVD 0.100 0.753
Smoking 1.217 0.273
Concomitant CAD 0.419 0.519
Atrial fibrillation 0.012 0.913
Lesion size on CT
(1.5 ml [IQR 0.1–77.5])
5.685 0.019
Laboratory
parameters
Creatinine
(1.0 mg/dl [IQR 0.9–1.1])
0.125 0.725
Creatine kinase
(86 U/l [IQR 56–150])
0.076 0.784
Glucose
(115.5 mg/dl [IQR 99.3–141])
0.509 0.478
C-reactive protein
(0.4 mg/dl [IQR 0.1–1.0]
0.163 0.688
Platelet count
(263  109/l [IQR 217.5–306.5])
0.131 0.718
Medication ACE inhibitors 1.394 0.241
Angiotensin-receptor blockers 0.599 0.441
Beta-blockers 0.015 0.904
Statins 0.251 0.618
Aspirin 0.001 0.981
Clopidogrel 0.016 0.900
Vitamin K antagonist 0.294 0.589
Group Stroke/TIA vs. no ischemia 15.493 0.001
CT  computed tomography; IQR  interquartile range; other abbreviations as in Table 1.without stroke (Fig. 1B). Elevated PENK-A levels inpatients with cardioembolism (TOAST2, 127.3 pmol/l
[91.6 to 167.9]) did not, however, reach the level of
significance (Fig. 1B). These results were paralleled for
PTA: elevated PTA levels were observed in the TOAST1
subgroup (64.2 pmol/l [48.9 to 91.1] vs. nonischemic; p 
0.05), but not in TOAST2 (50.6 pmol/l [35.3 to 68.5] vs.
nonischemic; nonsignificant) (Fig. 1D).
Comparing TOAST1 patients to patients with non-LAA
revealed a nonsignificant difference for PENK-A levels
(TOAST1 vs. non-LAA, 114.8 pmol/l [88.3 to 142]; p 0.057)
and a significant difference for PTA levels (TOAST1 vs. non-
LAA, 52.4 pmol/l [38.6 to 66]; p  0.002).
For both biomarkers, the patient number in other sub-
groups of stroke etiology (TOAST3 to TOAST5) was too
small to reach statistically significant levels between groups
(all p  0.05).
Discussion
The main findings of the present study are that plasma
concentrations of PENK-A are elevated in acute stroke
patients compared to patients with TIA and with nonisch-
emic events. The elevation of PENK-A correlated with
stroke severity as assessed by NIHSS score and with CT
brain lesion size. Further, elevated PENK-A concentrations
predicted 3-month outcome for all-cause mortality and for
the composite endpoint of death, stroke reoccurrence, and
myocardial infarction. Elevated PENK-A concentrations
were also predictive of more severe functional disability of
patients as assessed by mRS score. In contrast, PTA did not
show any discriminative power. This is the first study to
evaluate the impact of the precursor neuropeptides
PENK-A and PTA on outcome in patients with acute
cerebrovascular events.
In subgroup analysis for stroke etiology, a 40% increase of
PENK-A concentrations in patients with large-artery ath-
erosclerosis (TOAST1) was observed in comparison to
patients without stroke. Increase of PTA levels in patients
with large-artery atherosclerosis were less pronounced
(20%) and not different from nonischemic patients and
from patients with cardioembolic events (Fig. 1D).
Leakage of the BBB integrity is a relevant feature of
stroke pathophysiology. Measurement of the mature neu-
ropeptides in plasma is, however, complicated by rapid
physiologic degradation of the bioactive peptides and by low
in vitro stability. By contrast, assessment of stable fragments
of biological inactive precursor peptides has been shown to
circumvent this problem as they adequately reflect neuro-
peptide production and show high stability in human
plasma and for 48 h (6,7). For PTA and PENK, a 90 and
100 times higher concentration has been observed in cere-
brospinal fluid compared to plasma. These concentrations
gradients are among the highest recognized for a cerebro-
spinal fluid protein in human physiology.
Earlier studies found that determination of molecular
compounds derived from the BBB such as c-Fn and
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(24,25). However, these disruption markers of the BBB are
expressed differently, as an increase of c-Fn expression
seems to be more adequate for the prediction of hemor-
rhagic transformation (25). The field of prognostic bio-
markers in the ischemic stroke setting is increasingly in the
focus of ongoing research, and several candidates are being
evaluated such as natriuretic peptides, copeptin, MMP9,
Lp-PlA2, and others. Lipoprotein-associated phospholipase
A2 (Lp-PlA1) is involved in the development of arterioscle-
rosis and plaque rupture and predicts cardiovascular events
including stroke (26); Lp-PlA2 has been approved by the
Food and Drug Administration for assessing the risk of
ischemic stroke. Further work is warranted, however, to
establish novel biomarkers in the setting of ischemic stroke
for a similar successful use as in the management of cardiac
events.
Enkephalins have recently been used for the assessment
Figure 3 Clinical Outcome Assessed for PENK-A
Event-free survival of patients with acute stroke symptoms classified for proenkep
[open circles]) for (A) all-cause mortality and (B) the composite endpoint of all-ca
curves for 3-month outcome. (C) Functional testing after 3 months; patients have
found in patients with an enhanced PENK-A concentration compared to patients wof neuroinflammation and vascular dementia (27,8). In thepresent study, an association between high PENK-A ex-
pression and prediction of ischemic stroke has been shown,
in particular for patients with large-artery atherosclerosis
(TOAST1). Intriguingly, PENK-A concentration was sig-
nificantly lower in patients with TIA compared to patients
with ischemic stroke, reflecting the definition of TIA
“without evidence of infarction” (4).
An elevated PENK-A concentration showed a poor
clinical outcome for cumulative event-free survival and
composite endpoint at 3-month follow-up as well as for
mRS score. Our study observed a single-center cohort, and
the results need to be confirmed in larger and multicenter
populations. Three-month mortality was 12.6% in our
study, which is in the line with reports from other stroke
cohorts in comparable settings (28).
In contrast to the associations of PENK-A with stroke
severity and outcome, the results of PTA are more incon-
sistent, although we found a positive correlation between
(PENK-A) plasma levels (highest quartile [closed circles] vs. quartiles 1 to 3
ortality, nonfatal re-stroke, and myocardial infarction. Kaplan-Meier survival
assessed by modified Rankin scale (mRS). A high mRS score (score 3) was
er concentrations. CI  confidence interval; HR  hazard ratio.halin A
use m
been
ith lowthese 2 BBB disruption markers. This discrepancy cannot
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that both markers are not organo-specific, but particularly,
PTA is also expressed in inflammatory cells (29) and in the
gastrointestinal tract (30). However, multifactorial analysis
of covariance revealed that PENK-A and PTA plasma
concentrations were independent of possible confounders,
in particular, assessing laboratory markers such as creatinine,
creatine kinase, blood glucose, C-reactive protein, and
platelet count.
Over the last years, several single biomarkers have been
shown to help risk assessment in coronary artery disease
and ACS, but a multimarker strategy proved to be the
most efficient method for early risk stratification and for
future clinical practice (31). In comparison to cardiac
diseases, there is an unmet need for development of
reliable biomarkers in stroke, and a framework of criteria
for evaluation of the value of novel biomarkers has been
proposed (32). In the line with this consensus statement,
our study addresses the early phases of evaluation of
biomarkers in a proof-of-concept trial and demonstrating
outcome prediction in a prospective cohort.
Pursuing the pathophysiologic concept that acute BBB
changes are regulated by mast cells through release of
inflammatory and vasoactive mediators, BBB markers such
as PENK-A may have a potential role in monitoring
therapeutic effects to stabilize BBB after acute stroke (33).
Future studies should also evaluate the time course with
serial measurements of both biomarkers.
Study limitations. A major limitation to this study is that
patients with higher NIHSS score (12) were not included
in the study. The upper limit of NIHSS 12 was a prospec-
tively defined enrollment criterion due to the inability to
provide informed consent with more advanced stroke sever-
ity. Although the predictive value of PENK-A for the
MACCE composite endpoint is interesting, it may seem
difficult to explain at this stage on pathophysiological
grounds the association with stroke recurrence at the same
time.
In our study, we did not pursue a multimarker approach
to identify a promising candidate out of a range of variables.
We rather measured PENK-A and PTA on the basis of
pathophysiologic considerations and on the prospective
hypothesis that these markers are promising candidates to
indicated BBB damage. Moreover, the sample size of our
study cohort was rather small, and the confirmation of
our results in larger and independent samples is war-
ranted. Of note, the results of the analysis of covariance
with 23 numerators may be blurred by overfitting and
possible multicollinearity.
Conclusions
An elevated PENK-A expression was associated with the
clinical severity of ischemic stroke, with brain lesion size,
and with a poor clinical outcome. PENK-A and other
disruption markers of the BBB may be promising targets forbiomarker analysis in stroke. Future studies with larger
collectives should substantiate PENK-A as a disease marker
in ischemic stroke.
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